NASDAQ:MRTX | Jotup

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Retrieved on:

Wednesday, January 10, 2024

Patient, European, CHMP, Therapy, MD, SAN, Partnership, Civil service commission, European Commission, Cancer, Lung cancer, NSCLC, RECIST, Mirati Therapeutics, Mirati, Doctor of Philosophy, Committee, Physician, Pharmaceutical industry

"KRAZATI offers an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C -mutated NSCLC and this approval expands the potential treatment options available," Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Germany.

Key Points:

"KRAZATI offers an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C -mutated NSCLC and this approval expands the potential treatment options available," Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Germany.
"With it's differentiated profile, KRAZATI offers an impactful treatment option for patients living with lung cancer.
This authorization follows the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in November 2023.
Mirati thanks the patients, physicians, investigators and site coordinators who participated in the clinical trials that led to this important approval.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, GAN

Retrieved on:

Thursday, November 9, 2023

Bristol Myers Squibb, Sale, NSCLC, Fraud, Contingent value rights, Therapy, GAN, Advertising, Patient, Mirati Therapeutics, U.S. FDA, Security (finance), Mirati

If you are a Mirati shareholder, click here to learn more about your rights and options .

Key Points:

If you are a Mirati shareholder, click here to learn more about your rights and options .
If you are a GAN shareholder, click here to learn more about your rights and options .
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Retrieved on:

Wednesday, November 8, 2023

Class Action Lawsuit, Professional Services, Legal, BMY, Sale, NSCLC, NYSE, Contingent value rights, KSF, Bristol Myers Squibb, U.S. FDA, Patient, Pharmaceutical industry, Mirati

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, SP, MRTX

Retrieved on:

Saturday, November 4, 2023

Standard BioTools, Bristol Myers Squibb, Sale, NSCLC, SomaLogic, Fraud, Contingent value rights, Advertising, SP Plus Corporation, U.S. FDA, Patient, Mirati Therapeutics, Security (finance), Mirati

If you are a SomaLogic shareholder, click here to learn more about your rights and options .

Key Points:

If you are a SomaLogic shareholder, click here to learn more about your rights and options .
If you are a SP® Plus shareholder, click here to learn more about your rights and options .
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SIX, MRTX, FAZE, TGH

Retrieved on:

Friday, November 3, 2023

Bristol Myers Squibb, Sale, TGH, NYSE, Empire, Six Flags, Cedar Fair, Monteverde, SIX, Therapy, CVR, Mirati Therapeutics, Security (finance)

Under the terms of the agreement, SIX shareholders will receive 0.58 shares of the newly combined company per share they own.

Key Points:

Under the terms of the agreement, SIX shareholders will receive 0.58 shares of the newly combined company per share they own.
It is free and there is no cost or obligation to you.
Mirati Therapeutics, Inc. (Nasdaq: MRTX ), relating to its proposed sale to Bristol Myers Squibb.
Under the terms of the agreement, TGH shareholders will receive $50.00 in cash per share they own.

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Retrieved on:

Thursday, November 2, 2023

Mirati, NSCLC, Cancer, Patient, Mirati Therapeutics, Trial of the century, KURA, SAN, FTI, Pharmaceutical industry

“Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.

Key Points:

“Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
Preclinical work demonstrates the ability of adagrasib, in combination with a FTI, to improve patient outcomes,” said Alan Sandler, M.D., Chief Medical Officer, Mirati Therapeutics.
“This collaboration exemplifies the potential combinability of adagrasib as a key differentiation from other KRASG12C inhibitors.”
Under the terms of the agreement, Kura will sponsor the Phase 1 study of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC.
Mirati will supply Kura with adagrasib for the study.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MRTX, FAZE, HES, TGH

Retrieved on:

Friday, October 27, 2023

Hess Corporation, Chevron Corporation, Bristol Myers Squibb, Sale, TGH, NYSE, Empire, Monteverde, HES, Therapy, CVR, Mirati Therapeutics, Security (finance)

Under the terms of the agreement, MRTX shareholders will receive $58.00 and one CVR worth up to $12.00 in cash per share they own.

Key Points:

Under the terms of the agreement, MRTX shareholders will receive $58.00 and one CVR worth up to $12.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Under the terms of the agreement, FAZE shareholders will receive 0.13091 shares of GameSquare per share they own.
Under the terms of the agreement, TGH shareholders will receive $50.00 in cash per share they own.

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on:

Monday, November 6, 2023

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.

Key Points:

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
We look forward to continuing our work to improve the lives of people with cancer through Mirati discovered and developed therapeutics."
Excluding the August 2023 financing, net decrease in cash, cash equivalents and short-term investments for the third quarter of 2023 was $135.5 million.
Net KRAZATI product revenue for the three and nine months ended September 30, 2023 was $16.4 million and $36.1 million, respectively.

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Retrieved on:

Friday, November 3, 2023

PD-L1, United Kingdom, NSCLC, Medication, Mirati, Lung cancer, University Hospital (Newark, New Jersey), University Hospitals Birmingham NHS Foundation Trust, MHRA, Immunotherapy, Medicines and Healthcare products Regulatory Agency, Therapy, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry

"KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.

Key Points:

"KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.
"Fourteen percent of people living with NSCLC harbour the KRASG12C mutation yet there are limited targeted treatment options for patients with this devastating disease1,2," said Dr Shobhit Baijal (Consultant Medical Oncologist of The University Hospital Birmingham).
"The expansion of treatment options for NSCLC benefits patients and clinicians alike.
As someone intensively involved in the management of lung cancer patients, I look forward to KRAZATI being available for use in clinical practice."

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, MRTX, ORTX

Retrieved on:

Thursday, October 26, 2023

Bristol Myers Squibb, Sale, NSCLC, MLD, Orchard, Eli Lilly, Fraud, Contingent value rights, Advertising, ADS, U.S. FDA, Patient, Mirati Therapeutics, Kyowa Kirin, Security (finance), Mirati

If you are a POINT Biopharma shareholder, click here to learn more about your rights and options .

Key Points:

If you are a POINT Biopharma shareholder, click here to learn more about your rights and options .
If you are a Mirati shareholder, click here to learn more about your rights and options .
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.